BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now directly owns 8,397 shares of the company's stock, valued at approximately $251,910. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
BioXcel Therapeutics Stock Up 2.8 %
Shares of NASDAQ:BTAI opened at $32.01 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 10.28 and a current ratio of 10.34. BioXcel Therapeutics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.96. The stock has a market capitalization of $896.98 million, a P/E ratio of -6.55 and a beta of 1.16. The stock has a 50-day simple moving average of $21.69 and a 200-day simple moving average of $16.43.
Get
BioXcel Therapeutics alerts:
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.15). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.05 million. Equities analysts forecast that BioXcel Therapeutics, Inc. will post -5.37 earnings per share for the current year.
Analysts Set New Price Targets
BTAI has been the subject of several analyst reports. Canaccord Genuity Group boosted their target price on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research note on Friday, November 11th. Mizuho boosted their target price on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research note on Thursday, December 15th. Guggenheim cut their target price on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, November 11th. Canaccord Genuity Group lifted their price target on BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a report on Friday, November 11th. Finally, HC Wainwright lowered their price target on BioXcel Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a report on Tuesday, January 3rd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, BioXcel Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $52.89.
Hedge Funds Weigh In On BioXcel Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of BTAI. Millennium Management LLC boosted its holdings in BioXcel Therapeutics by 872.6% in the 2nd quarter. Millennium Management LLC now owns 188,548 shares of the company's stock worth $2,489,000 after acquiring an additional 169,163 shares during the period. Nuveen Asset Management LLC raised its position in shares of BioXcel Therapeutics by 95.5% in the 3rd quarter. Nuveen Asset Management LLC now owns 217,624 shares of the company's stock valued at $2,572,000 after purchasing an additional 106,314 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioXcel Therapeutics by 330.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 125,280 shares of the company's stock valued at $2,620,000 after purchasing an additional 96,180 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of BioXcel Therapeutics by 569.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 91,039 shares of the company's stock valued at $1,202,000 after purchasing an additional 77,449 shares in the last quarter. Finally, State Street Corp raised its position in shares of BioXcel Therapeutics by 4.1% during the 1st quarter. State Street Corp now owns 1,400,753 shares of the company's stock valued at $29,290,000 after acquiring an additional 55,657 shares in the last quarter. Hedge funds and other institutional investors own 42.35% of the company's stock.
About BioXcel Therapeutics
(Get Rating)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Articles
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
